Showing 6251-6260 of 7671 results for "".
- Topical PDE4 Inhibitor from Arcutis Shows Benefit in Seborrheic Dermatitishttps://practicaldermatology.com/news/topical-pde4-inhibitor-from-arcutis-shows-benefit-in-seborrheic-dermatitis/2460544/Positive topline data from a Phase 2 clinical trial suggest ARQ-154 (topical roflumilast foam) from Arcutis Biotherapeutics, Inc. is a potential treatment for seborrheic dermatitis. Study results show that roflumilast foam 0.3%
- Tattoos Impair Sweating, May Increase Risk of Heat-related Injuryhttps://practicaldermatology.com/news/tattoos-impair-sweating-may-increase-risk-of-heat-related-injury/2460539/New research finds that tattooed skin does not sweat as much as non-inked areas, which may have implications for the body’s ability to cool in people with extensive tattooing.
- Hoth Therapeutics’ HT-003 Inhibits Acne Gene TLR2https://practicaldermatology.com/news/hoth-therapeutics-ht-003-inhibits-acne-gene-tlr2/2460538/Hoth Therapeutics, Inc. completed testing on the ability of HT-003 to block acne pathogenic gene expression in human keratinocytes. Initial data from the first phase of the research reports that toll-like receptor 2 (TLR2) is significantly
- Suneva to Market and Distribute Neauvia's Plasma IQ in North Americahttps://practicaldermatology.com/news/suneva-to-market-and-distribute-neauvias-plasma-iq-in-north-america/2460534/Suneva Medical, Inc., will market and distribute Neauvia Plasma IQ throughout North America as part of a new partnership. The first Class 2 FDA-cleared plasma energy device, Plasma IQ delivers focused, controlled plasma energy to create microinjuries on the skin, renewing
- Medimetriks Streamlines MM36 AD Development Programhttps://practicaldermatology.com/news/medimetriks-streamlines-mm36-ad-development-program/2460532/Medimetriks Pharmaceuticals, Inc. is moving forward with its MM36 (difamilast) Atopic Dermatitis Development Program following a meeting with the U.S. Food and Drug Administration (FDA). Medimetriks is now preparing to conduct a s
- First Patient Enrolled in AVITA Therapeutic’s Pivotal Study of RECELL System for Vitiligohttps://practicaldermatology.com/news/first-patient-enrolled-in-avita-therapeutics-pivotal-study-of-recell-system-for-vitiligo/2460528/AVITA Therapeutics, Inc. a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs initiated its pivotal study assessing the use of the RECELL System to treat stable vitiligo with th
- New Allergan Aesthetics and Skinbetter Initiative Aims to Advance Health Equity and Diversity in Aestheticshttps://practicaldermatology.com/news/new-initiative-allergan-aesthetics-and-skinbetter-aims-to-advance-health-equity-and-diversity-in-aesthetics/2460526/Allergan Aesthetics, an AbbVie company, and Skinbetter Science have launched a new long-term, educational initiative—DREAM: Driving Racial Equity in Aesthetic Medicine—to further the principles of racial and ethnic diversity, inclusion, respect and understanding in the fields of derma
- Partner Therapeutics Moves Ahead with Phase 3 Study of Leukine Plus Ipilumimab and Nivolumab for Melanomahttps://practicaldermatology.com/news/partner-therapeutics-moves-ahead-with-phase-3-study-of-leukine-plus-ipilumimab-and-nivolumab-for-melanoma/2460524/Partner Therapeutics, Inc. is resuming enrollment in the National Cancer Institute (NCI)-sponsored ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) study of Leukine plus Ipilumimab and Nivolumab for Melanoma following a successful planned interim analysis. EA6141 (
- Dr. Doris Day Joins Nufabrx’s Ad Boardhttps://practicaldermatology.com/news/dr-doris-day-joins-nufabrxs-ad-board/2460523/New York City dermatologist Doris Day, MD is the newest member of Nufabrx’s advisory board. Nufabrx is an advanced textiles company that has developed a proprietary biomaterial platform that embeds active ingredients into fabrics to 
- Remembering 9-11: A Dermatology Perspectivehttps://practicaldermatology.com/news/remembering-9-11-a-dermatology-perspective/2460522/New research takes a close look at dermatologic injuries and chronic skin conditions that have affected survivors and responders during the nearly two decades since the terrorist attacks on September 11, 2001. These chronic illnesses include sarcoidosis, autoimmune disease, ill-defined